Last reviewed · How we verify

Regadenoson peripheral - central

Lokien van Nunen · Phase 3 active Small molecule

Regadenoson is an adenosine A2A receptor agonist that causes coronary vasodilation to increase blood flow, used for cardiac stress testing.

Regadenoson is an adenosine A2A receptor agonist that causes coronary vasodilation to increase blood flow, used for cardiac stress testing. Used for Pharmacologic stress agent for myocardial perfusion imaging in patients unable to exercise.

At a glance

Generic nameRegadenoson peripheral - central
SponsorLokien van Nunen
Drug classAdenosine A2A receptor agonist
TargetAdenosine A2A receptor
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

Regadenoson selectively binds to adenosine A2A receptors on coronary vascular smooth muscle, triggering vasodilation and increasing coronary blood flow without the systemic effects of non-selective adenosine agonists. This allows assessment of myocardial perfusion during pharmacologic stress testing in patients unable to exercise. The peripheral-central designation likely refers to the route of administration or distribution characteristics in this phase 3 formulation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: